PDCD1 and neoplasm: To date, preliminary results suggest that anti-CD73 mAbs and PD-1 blockade represent a promising approach with an acceptable safety profile in several tumor subtypes such as metastatic melanoma (90), encouraging future therapeutic applications in the clinical practice.